SFTPD and interstitial lung disease: In contrast, patients with stable ILD experienced a significant reduction in SP-D levels, from 241 ng/mL at baseline to a 19.5% decrease (to 194 ng/mL) at 3 months and 19% (to 195 ng/mL) at the end of 6 months compared to baseline.